These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 29294598)

  • 21. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX.
    Choy E; McKenna F; Vencovsky J; Valente R; Goel N; Vanlunen B; Davies O; Stahl HD; Alten R
    Rheumatology (Oxford); 2012 Jul; 51(7):1226-34. PubMed ID: 22344576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials.
    Tanaka Y; Takeuchi T; Haaland D; Hall S; Inanc N; Li Z; Xavier RM; Cara C; Tilt N; Taylor PC
    Int J Rheum Dis; 2023 Jul; 26(7):1248-1259. PubMed ID: 37195063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiographic remission in rheumatoid arthritis quantified by computer-aided joint space analysis (CASJA): a post hoc analysis of the RAPID 1 trial.
    Pfeil A; Nussbaum A; Renz DM; Hoffmann T; Malich A; Franz M; Oelzner P; Wolf G; Böttcher J
    Arthritis Res Ther; 2020 Oct; 22(1):229. PubMed ID: 33023661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.
    Glatt S; Taylor PC; McInnes IB; Schett G; Landewé R; Baeten D; Ionescu L; Strimenopoulou F; Watling MIL; Shaw S
    Ann Rheum Dis; 2019 Aug; 78(8):1033-1040. PubMed ID: 31177099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial.
    Keystone EC; Curtis JR; Fleischmann RM; Furst DE; Khanna D; Smolen JS; Mease PJ; Schiff MH; Coteur G; Davies O; Combe B
    J Rheumatol; 2011 Jun; 38(6):990-6. PubMed ID: 21362764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
    Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
    Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.
    Smolen J; Landewé RB; Mease P; Brzezicki J; Mason D; Luijtens K; van Vollenhoven RF; Kavanaugh A; Schiff M; Burmester GR; Strand V; Vencovsky J; van der Heijde D
    Ann Rheum Dis; 2009 Jun; 68(6):797-804. PubMed ID: 19015207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of methotrexate plus certolizumab pegol or placebo in active rheumatoid arthritis : Meta-analysis of randomized controlled trials.
    Lee YH; Bae SC
    Z Rheumatol; 2017 Aug; 76(6):528-534. PubMed ID: 27312466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis.
    Tanaka Y; Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
    Int J Rheum Dis; 2020 Mar; 23(3):316-324. PubMed ID: 31957303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study.
    Sarzi-Puttini P; Filippucci E; Adami S; Meroni PL; Batticciotto A; Idolazzi L; De Lucia O; Talavera P; Kumke T; Grassi W
    Adv Ther; 2018 Aug; 35(8):1153-1168. PubMed ID: 30043210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study.
    Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Sep; 24(5):725-33. PubMed ID: 24372225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study.
    Weinblatt ME; Fleischmann R; Huizinga TW; Emery P; Pope J; Massarotti EM; van Vollenhoven RF; Wollenhaupt J; Bingham CO; Duncan B; Goel N; Davies OR; Dougados M
    Rheumatology (Oxford); 2012 Dec; 51(12):2204-14. PubMed ID: 22923753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
    Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
    Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.
    Keystone E; Landewé R; van Vollenhoven R; Combe B; Strand V; Mease P; Shaughnessy L; VanLunen B; van der Heijde D
    Ann Rheum Dis; 2014 Dec; 73(12):2094-100. PubMed ID: 23918037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Matrix metalloproteinase-3 and the 7-joint ultrasound score in the assessment of disease activity and therapeutic efficacy in patients with moderate to severe rheumatoid arthritis.
    Zhou L; Wang G; Liu X; Song J; Chen L; Xu H
    Arthritis Res Ther; 2017 Nov; 19(1):250. PubMed ID: 29141665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of periarticular bone loss is associated with clinical remission and ACR70-Response in rheumatoid arthritis.
    Pfeil A; Nussbaum A; Renz DM; Jung C; Oelzner P; Malich A; Wolf G; Böttcher J
    Rheumatol Int; 2019 Apr; 39(4):637-645. PubMed ID: 30569216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study.
    Weinblatt ME; Mease P; Mysler E; Takeuchi T; Drescher E; Berman A; Xing J; Zilberstein M; Banerjee S; Emery P
    Arthritis Rheumatol; 2015 Oct; 67(10):2591-600. PubMed ID: 26138593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial.
    Hara M; Ishiguro N; Katayama K; Kondo M; Sumida T; Mimori T; Soen S; Nagai K; Yamaguchi T; Yamamoto K;
    Mod Rheumatol; 2014 May; 24(3):410-8. PubMed ID: 24252050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, double-blind, and placebo-controlled multicenter clinical trial of a novel cytotoxic T-lymphocyte antigen-4 fusion protein, Leining, in Chinese active rheumatoid arthritis patients with an inadequate response to methotrexate.
    Fan W; Zhao DB; Hu SX; Xu HJ; Zhang X; Zhang MJ; Chen ZW; Zhang FX; Zhu P; Li XF; Bi LQ; Zhou B; Bao CD
    Rheumatol Int; 2014 Nov; 34(11):1519-27. PubMed ID: 24671501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.